CMN Markets October 2021 | CRISPR Stocks and...
Nov. 3, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Takeda Pharmaceutical Company
Main focus (gene editing): Treatment of genetic diseases
Company stage: Commercial
Diseases (gene editing): Liver- and haematopoietic stem cell (HSC)-directed indications
Genome editing tool: Cas-CLOVER™, OMNI™ Nuclease
Funding stage: Public (NASDAQ: TAK)
Location: Tokyo, Japan
Website: https://www.takeda.com/
Pipeline: https://www.takeda.com/what-we-do/research-and-development/our-pipeline/
Partners: Poseida Therapeutics, Sangamo Therapeutics, LogicBio Therapeutics, EmendoBio (AnGes)
Takeda Pharmaceutical Company (Takeda) is a multi-national commercial company with many divisions and focus areas. The company's engagement in gene editing comes through collaborations with companies such as Poseida Therapeutics and EmendoBio. The recent collaboration with Poseida allows Takeda to use the Cas-CLOVER technology to develop gene therapies targeting liver and blood-related diseases.
